RT Journal Article
SR Electronic
T1 KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <em>BRAF</em>-mutant melanoma
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e001806
DO 10.1136/jitc-2020-001806
VO 8
IS 2
A1 Ferrucci, Pier Francesco
A1 Di Giacomo, Anna Maria
A1 Del Vecchio, Michele
A1 Atkinson, Victoria
A1 Schmidt, Henrik
A1 Schachter, Jacob
A1 Queirolo, Paola
A1 Long, Georgina V
A1 Stephens, Rosalie
A1 Svane, Inge Marie
A1 Lotem, Michal
A1 Abu-Amna, Mahmoud
A1 Gasal, Eduard
A1 Ghori, Razi
A1 Diede, Scott J
A1 Croydon, Elizabeth S
A1 Ribas, Antoni
A1 Ascierto, Paolo Antonio
A1 
YR 2020
UL http://jitc.bmj.com/content/8/2/e001806.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.